QUINCE THERAPEUTICS Files 8-K Flagging Listing Rule Issue
The biotech filed an Item 3.01 disclosure with the SEC covering a delisting notice or failure to meet a continued listing standard, dated August 31, 2026.
The biotech filed an Item 3.01 disclosure with the SEC covering a delisting notice or failure to meet a continued listing standard, dated August 31, 2026.